Clinical trials
Phase 1 Carcinoma, Non-Small-Cell Lung trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
114 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 5 |
| 2017 | 10 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 8 |
| 2021 | 11 |
| 2022 | 7 |
| 2023 | 12 |
| 2024 | 18 |
| 2025 | 7 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 41 |
| Active, not recruiting | 25 |
| Recruiting | 25 |
| Terminated | 19 |
| Unknown status | 3 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 12 |
| AbbVie | 8 |
| AstraZeneca | 6 |
| Eli Lilly and Company | 6 |
| Amgen | 5 |
| Exelixis | 3 |
| Genentech, Inc. | 3 |
| MacroGenics | 3 |
| Pfizer | 3 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 114 |
| Colorectal Neoplasms | 38 |
| Neoplasms | 27 |
| Squamous Cell Carcinoma of Head and Neck | 24 |
| Triple Negative Breast Neoplasms | 23 |
| Melanoma | 22 |
| Ovarian Neoplasms | 22 |
| Breast Neoplasms | 19 |
| Neoplasm Metastasis | 19 |
| Carcinoma, Renal Cell | 18 |
Trials
Showing 1 to 25 of 114. Each trial links to its page on Pharma Observatory.
14 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.